Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy

Benzer Materyaller

• Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma
  Yazar:: Joshua N. Gustine, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-06-01)
• Impact of body mass index on anti-BCMA chimeric antigen receptor T-cell therapy outcomes in multiple myeloma
  Yazar:: Ruth Choa, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-12-01)
• Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy
  Yazar:: Jessica S. Little, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-08-01)
• Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy
  Yazar:: Masooma Shifa Rana, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-04-01)
• sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
  Yazar:: Katja Seipel, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-03-01)